Fusion Pharm Stock Buy Hold or Sell Recommendation
| FSPM Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Fusion Pharm is 'Strong Sell'. The recommendation algorithm takes into account all of Fusion Pharm's available fundamental, technical, and predictive indicators you will find on this site.
Check out Fusion Pharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide. Note, we conduct extensive research on individual companies such as Fusion and provide practical buy, sell, or hold advice based on investors' constraints. Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Fusion |
Execute Fusion Pharm Buy or Sell Advice
The Fusion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fusion Pharm. Macroaxis does not own or have any residual interests in Fusion Pharm or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fusion Pharm's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Fusion Pharm Trading Alerts and Improvement Suggestions
| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 67.01 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures |
Fusion Pharm Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fusion Pharm or Consumer Staples Distribution & Retail sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fusion Pharm's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fusion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Fusion Pharm Volatility Alert
At this time Fusion Pharm exhibits very low volatility. Fusion Pharm appears to be a penny stock. Although Fusion Pharm may be, in fact, a solid short-term or long term investment, many penny stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Fusion Pharm or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Fusion instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Fusion Pharm Fundamentals Vs Peers
Comparing Fusion Pharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fusion Pharm's direct or indirect competition across all of the common fundamentals between Fusion Pharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fusion Pharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fusion Pharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Fusion Pharm by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Fusion Pharm to competition |
| Fundamentals | Fusion Pharm | Peer Average |
| Return On Asset | -1.38 | -0.14 |
| Profit Margin | (1.11) % | (1.27) % |
| Operating Margin | (1.24) % | (5.51) % |
| Current Valuation | 294.63 K | 16.62 B |
| Shares Outstanding | 10.59 M | 571.82 M |
| Price To Earning | (0.07) X | 28.72 X |
| Price To Sales | 0 X | 11.42 X |
| Revenue | 594.4 K | 9.43 B |
| Gross Profit | 67.01 K | 27.38 B |
| Net Income | (42.08 K) | 570.98 M |
| Cash And Equivalents | 1.45 K | 2.7 B |
| Total Debt | 1.2 K | 5.32 B |
| Current Ratio | 0.73 X | 2.16 X |
| Book Value Per Share | (0.07) X | 1.93 K |
| Cash Flow From Operations | 239.84 K | 971.22 M |
| Earnings Per Share | (0.15) X | 3.12 X |
| Number Of Employees | 4 | 18.84 K |
| Beta | -20.67 | -0.15 |
| Market Capitalization | 1.06 K | 19.03 B |
| Total Asset | 4.04 K | 29.47 B |
| Retained Earnings | (9.11 K) | 9.33 B |
| Working Capital | 728 K | 1.48 B |
| Current Asset | 1.19 M | 9.34 B |
| Current Liabilities | 459 K | 7.9 B |
| Net Asset | 4.04 K |
Fusion Pharm Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fusion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Fusion Pharm Buy or Sell Advice
When is the right time to buy or sell Fusion Pharm? Buying financial instruments such as Fusion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Fusion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 272 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Fusion Pharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.